AUROPHARMA · NSE · Pharmaceuticals
Aurobindo Pharma Ltd
What the numbers mean, from its filings and the exchange. Data as of 12 Oct 2026.
Mid Cap · AMFI list Jan-Jun 2026 · Vendor sector: Basic Materials
cheap
low confidence
No valuation within 120 days; P/E 26.4 vs peers 42.8 (3rd of 23); P/B 3.3 vs peers 7.2 (7th of 25).
Statements through FY2026Prices adjusted for corporate actionsNot yet reviewed by the adversarial model
What is Aurobindo Pharma's share price today?
Aurobindo Pharma last traded at ₹1,706.90 on the NSE, as of 12 Oct 2026, 11:00 pm IST, up 0.8% on the day, up 48.9% over a year. Its 52-week range is ₹1,067 to ₹1,740. The live price is in the app.
₹1,706.90
+0.8% today
+48.9% over 1 year · NSE, as of 12 Oct 2026, 11:00 pm IST
60 month-end closes, 31 Oct 2021 to 30 Sep 2026, adjusted for splits and bonuses
52-week range95% of the way up
Low ₹1,067High ₹1,740
What is Aurobindo Pharma's market cap?
Aurobindo Pharma's market capitalisation is about ₹97,411 crore: what it would cost to buy every share at today's price. That makes it the 22nd largest mid cap company we cover.
₹97,411 Cr
Mid Cap22nd largest mid cap company
Share price₹1,707
×
Shares in issue57 crore
=
Market cap₹97,411 Cr
Mid Cap means the companies ranked 101 to 250 by size, under SEBI's rules. Shares in issue are worked out from the market cap and the price. What market cap tells you →
Key facts
From the exchange
- Symbol
- NSE: AUROPHARMA
- ISIN
- INE406A01037
- Cap bucket
- Mid Cap, 22nd largest by market cap
- Industry (NSE)
- Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
- Listed since
- 2000
- Futures and options
- Traded
Is Aurobindo Pharma overvalued?
Cheap, with low confidence: no valuation within 120 days; P/E 26.4 vs peers 42.8 (3rd of 23); P/B 3.3 vs peers 7.2 (7th of 25).
Valuation
Latest price and trailing 12 months
P/E
26.45
vs peers 42.8 · 3rd of 23
Price divided by last year's earnings per share: how many years of today's profit you pay for. Learn more →
P/B
3.33
vs peers 7.2 · 7th of 25
Price divided by book value per share: what you pay for each rupee of net assets on the balance sheet. Learn more →
Market cap
₹97,411 Cr
Total market value of all shares, in ₹ crore. Learn more →
Dividend yield
0.3%
vs peers 0.4% · 11th of 19
Last year's dividends as a share of today's price. Learn more →
PEG (vendor)
4.66
vs peers 2.4 · 12th of 19
P/E divided by the vendor's earnings growth figure, which it does not disclose; a P/E adjusted for how fast profits grow. Learn more →
PEG on our 3-year EPS growth
1.18
P/E divided by the 3-year EPS growth rate from the stored accounts. Learn more →
Is Aurobindo Pharma a quality business?
Quality score 30.1, 20th of 24 in its peer set; WATCH on 30 of 30 flags judged.
Quality and risk
Data as of 12 Oct 2026
Business quality
Not available
The kind of business, which sets the yardstick it is judged by. Learn more →
Quality score
30.1
vs peers 53.7 · 20th of 24
Returns, margins, leverage and consistency against its peers, out of 100. Learn more →
Risk level
WATCH
30 of 30 flags judged
From flags on debt, earnings quality, dilution and price swings. Learn more →
Profitability
ROE
11.2%
vs peers 16.2% · 19th of 25
Return on equity: profit as a share of shareholders' money. Learn more →
ROCE
12.9%
vs peers 19.0% · 20th of 25
Return on capital employed: operating profit as a share of all the capital in the business, debt and equity. Learn more →
Profit margin
10.4%
vs peers 14.8% · 19th of 24
Profit after everything, as a share of revenue. Learn more →
EPS
₹60.31
Trailing 12 months
Profit for each share over the last 12 months.
Inside the app
Get a sneak peek of Valarth
Has Aurobindo Pharma made money for shareholders?
Yes: +48.9% over one year and +18.2% a year over five years.
Shareholder returns
5-year return
+18.2% a year
Price only
Yearly average price return over five years, bonuses and splits adjusted. Learn more →
Wealth destroyer
No
Five-year total return — price CAGR on bonus- and split-adjusted closes plus the dividend yield — below the 7% a bank fixed deposit paid. Learn more →
Returns
3Y and 5Y are yearly averages
1W
+1.1%1M
+2.0%3M
+9.3%6M
+26.4%1Y
+48.9%3Y
+25.3%5Y
+18.2%Does Aurobindo Pharma pay a dividend?
Yes. Aurobindo Pharma's dividend yield is 0.31% at the latest price; the last payout was ₹4.00 a share, ex-dividend 8 Aug 2025.
Dividends
Per share, by ex-dividend date
Dividend yield0.31%
The past 12 months' dividends as a share of today's price.
8 Aug 2025 · Interim₹4.00
20 Feb 2024 · Interim 2₹1.50
20 Nov 2023 · Interim 1₹3.00
17 Feb 2023 · Interim 1₹3.00
6 Jun 2022 · Interim 4₹4.50
Payout ratio🔒 In the app
The share of profit paid out as dividends; a very high share leaves little to reinvest.
Dividend growth, 5 years🔒 In the app
How fast the dividend per share has grown a year.
Years without a miss🔒 In the app
How many years in a row a dividend has been paid.
Is Aurobindo Pharma growing?
Revenue 3 years 10.7% a year; profit 3 years 22.1% a year; revenue 5 years 8.3% a year.
Growth
Statements through FY2026 (Mar-26)
Revenue 3 years
10.7% a year
vs peers 14.3% · 17th of 24
Compound annual growth of revenue over three years. Learn more →
Profit 3 years
22.1% a year
vs peers 20.2% · 9th of 21
Compound annual growth of net profit over three years. Learn more →
Revenue 5 years
8.3% a year
Compound annual growth of revenue over five years. Learn more →
Profit 5 years
7.0% a year
Compound annual growth of net profit over five years. Learn more →
EPS 3 years
22.4% a year
Growth in earnings per share, so dilution counts against the company. Learn more →
EPS 5 years
-7.9% a year
Growth in earnings per share over five years, so dilution counts against the company. Learn more →
P/E vs own history
40.3%
vs peers 8.7% · 15th of 19
Today's P/E against its own 5-year median; negative is cheaper than its history. Learn more →
How did Aurobindo Pharma do last quarter?
Aurobindo Pharma reported revenue of ₹9,106 Cr, up 6.1% on a year earlier and a net profit of ₹1,032 Cr, up 0.6% in the Jun 2026 quarter.
Latest quarter
Jun 2026
Revenue, latest quarter₹9,106 Cr
+6.1% on a year earlier
What the company took in over the quarter.
Net profit, latest quarter₹1,032 Cr
+0.6% on a year earlier
What was left for shareholders after every cost and tax.
How does Aurobindo Pharma compare with its peers?
Compared with 24 Pharmaceuticals; 3rd of 23 on P/E; 20th of 24 on quality score.
Compared with 24 Pharmaceuticals
24 companies
- Aurobindo Pharma Ltd (this page)
- Divis Laboratories Ltd
- Torrent Pharmaceuticals Ltd
- Zydus Lifesciences Ltd
- Laurus Labs Ltd
- Cipla Ltd
- Dr Reddys Laboratories Ltd
- Mankind Pharma Ltd
- Lupin Ltd
- Glenmark Pharmaceuticals Ltd
- Alkem Laboratories Ltd
- Biocon Ltd
- Abbott India Ltd
- Gland Pharma Ltd
- Ipca Laboratories Ltd
- Glaxosmithkline Pharmaceuticals Ltd
- Ajanta Pharma Ltd
- J B Chemicals & Pharmaceuticals Ltd
- Emcure Pharmaceuticals Ltd
- Wockhardt Ltd
- Sai Life Sciences Ltd
- Neuland Laboratories Ltd
- Piramal Pharma Ltd
- Acutaas Chemicals Ltd
- Rubicon Research Ltd
Aurobindo Pharma against its peers
Largest 10 of 24 peers, by market cap
CompanyMarket capP/EP/BROEROCE1YQuality 🔒Rank 🔒
Aurobindo Pharma Ltd₹97,411 Cr26.43.311.2%12.9%+48.9%
Peer median—42.87.216.2%19.0%+32.4%
Market cap in rupees crore; P/E and P/B on the latest price; 1Y is the price return over a year. A dash is a figure that does not apply or is not reported.
Who owns Aurobindo Pharma?
Aurobindo Pharma is held by promoters 51.9%, foreign institutions 16.4%, domestic institutions 25.1%.
Shareholding pattern
Latest filing, percent of shares
Promoters51.9%
The founders and controlling group.
Foreign institutions16.4%
Overseas funds investing through the FPI route.
Domestic institutions25.1%
Indian insurers, banks, pension and mutual funds together.
Mutual funds16.7%
Indian mutual fund schemes; part of domestic institutions.
Retail and others5.0%
Individual investors and everyone else.
Promoter shares pledged🔒 In the app
Promoter shares given as collateral for loans; a high share is a risk to watch.
Holding trend🔒 In the app
Whether promoters, foreign funds and mutual funds have been adding or selling over recent quarters.
What do analysts say about Aurobindo Pharma?
26 analysts cover Aurobindo Pharma, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.
Analyst consensus
26 analysts
ConsensusBuy
The rating most covering analysts give the share.
Average target price🔒 In the app
The mean of the analysts' 12-month price targets.
Upside to target🔒 In the app
How far the target sits above or below today's price.
Share rating it a buy🔒 In the app
The share of covering analysts with a buy rating.
What does Aurobindo Pharma do and what is it sensitive to?
A multi-continent pharmaceutical company manufacturing and exporting active pharmaceutical ingredients (APIs) and finished formulations across 150+ countries. Sensitive to: foreign exchange fluctuations.
Business-model card
FY2026 · 57 verified
5Revenue
4Channels
5Regulators
7Reg. dependencies
4Sensitivities
6Costs
4Geographies
A multi-continent pharmaceutical company manufacturing and exporting active pharmaceutical ingredients (APIs) and finished formulations across 150+ countries. It earns revenue from sales of generic drugs, dermatology products, and specialty therapeutics to customers in regulated markets including the US, Europe, and growth markets, supported by a diversified portfolio of 728 approved products.
Revenue by segment
year ended March 31, 2026
Europe66.9%
Rest of the world33.1%
Revenue engine
5 verified
US market revenue
The US is described as 'our largest market by revenue contribution' with significant concentration and dependency on this geography, representing a major revenue segment.
Europe market revenue
Europe constitutes a key revenue market alongside the US, described as one of the company's major revenue markets.
Anti-retroviral (ARV) segment revenue
The company supplies ARV products to over 125 countries through global tenders issued by organizations such as the Global Fund, USAID/PEPFAR, and various Ministries of Health.
2 more statements
Growth Markets revenue
The company operates across growth markets including South Africa, Brazil, Canada, and regions across Africa as part of its geographic expansion strategy to support resilience and affordable access.
Domestic (India) market revenue
Company has presence in domestic markets where pricing dynamics are influenced by global trends in availability and cost of imported raw materials and APIs, with focus on affordability and accessibility.
Customers & channels
4 verified
Dealers and distributors channel (66.0%)
In FY26, 65.99% of sales made to dealers/distributors (658 such entities), with top 10 dealers/distributors accounting for 51.10% of sales to this channel.
Healthcare professionals and patients
Company engages healthcare professionals through meetings, conferences and seminars to understand patient needs, gather feedback on therapies and support responsible product development.
Global tender procurement via organizations
Supplies ARV products to 125+ countries through global tenders from Global Fund, USAID/PEPFAR, and Ministries of Health, representing a distinct government procurement channel.
1 more statement
Direct customers (wholesale, retail chains, group purchasing organizations)
Company sells to consolidated drug wholesalers, retail chains, and group purchasing organizations which have strengthened bargaining power, representing key direct channels in US and Europe.
Regulators
5 verified
US Food and Drug Administration (FDA) and US pricing authorities
Governs manufacturing, marketing and pricing of pharmaceutical products in the US market; government initiatives aimed at reducing drug prices create intensifying pricing pressures.
European regulatory authorities
Govern product approvals, manufacturing standards and market access in Europe, one of the company's major revenue markets.
National pharmaceutical regulators across 150+ countries
Govern product approvals, manufacturing compliance, and market access across the company's export footprint.
2 more statements
Ministry of Health and global health organizations (Global Fund, USAID/PEPFAR)
Issue global tenders and govern procurement of ARV products across 125+ countries, representing regulatory and procurement gatekeepers for this segment.
Domestic Indian regulators (drugs authority, pricing authority)
Govern product manufacturing, pricing and market access in India, the company's domestic market and manufacturing base.
Regulatory dependencies
7 verified
US drug price controls and government pricing regulations
Evolving pricing regulations and sustained pricing pressures may limit financial benefits from market expansion and new product launches; increased discounting to retain market share can reduce margins and adversely impact revenues and profitability.
Regulatory approval requirements for new products
Compliance with regulatory requirements is necessary to manufacture, market, or launch products in key markets; failure to comply may render offerings non-competitive and disrupt operations.
Production Linked Incentive (PLI) scheme and state-level incentives
Government initiatives supporting development of additional API capacities, new API parks and brownfield expansions, accelerating multi-site manufacturing capabilities and reducing costs.
4 more statements
Price controls and industry-wide competitive discounting requirements in domestic market
Industry-wide price controls, competitive discounting, and need to maintain price parity add pressure on realisations; pricing dynamics influenced by global trends in imported raw materials and APIs availability.
Geopolitical policy changes and regulatory framework evolution across markets
Economic or political instability, policy changes, and evolving regulatory frameworks across markets may impact operations, delay regulatory approvals, affect participation in global tenders, increase compliance costs and create barriers to market access.
Local manufacturing requirements and import restrictions in Africa, Middle East and Russia
Mandatory government tender procurement, local manufacturing push and import restrictions create high business risk in these regions; company participates aggressively in government tenders to de-risk.
Labour Codes (2020) and employee benefit regulations
Government of India notified four Labour Codes consolidating 29 labour laws, introducing uniform wage definitions and enhanced benefits; resulted in increase in gratuity liability (past service cost) and leave liability of Rs 173.8 million.
Sensitivities
4 verified
Foreign exchange fluctuations
Weakening of functional currency adversely impacts cost of imports and borrowings; however, export revenue may be favourably impacted. Company proactively monitors financial markets to minimise adverse impact.
Crude oil price volatility
Rising crude oil prices increase freight costs and insurance costs due to extended transit times, disrupting supply chains; geopolitical uncertainties and conflicts can fluctuate crude prices.
Global inflation and commodity prices
Cost of raw materials forms the largest portion of cost of revenues; commodity prices fluctuate significantly in short periods. Raw material price volatility directly impacts COGS and profitability.
1 more statement
Global recession and macroeconomic instability
Global recession, geopolitical tensions, rising inflation, and volatility affect operations, supply chain efficiency, logistics, production, demand-supply dynamics, and customer deliveries, impacting sales, profitability and cash flows.
Cost inputs
6 verified
Raw materials and active pharmaceutical ingredients (APIs) (44.0%)
44% of raw-material requirement (APIs plus Excipients) procured from China (including Hong Kong), 9% from other countries, 47% from domestic market; forms largest portion of cost of revenues and subject to commodity price fluctuations.
Packing materials
Cost of packing material consumed in FY25 was Rs 7,231.7 million for continuing operations, representing significant cost input in manufacturing.
Employee costs (salaries, wages, benefits)
Total employee benefits expense for FY25 was Rs 10,630.7 million including salaries, provident fund contributions, gratuity, compensated absences and staff welfare.
3 more statements
Contract manufacturing organization (CMO) capacity costs
Company has secured long-term capacity through 3-4 year agreements with multiple CMOs including assured volumes, technology transfer rights, and structured pricing mechanisms.
Finance costs and borrowing expenses
Interest expense on financial liabilities for FY25 was Rs 2,261.1 million; total finance costs including lease interest and other borrowing costs were Rs 2,300.4 million.
Transportation, logistics and freight costs
Logistics costs impacted by crude oil price volatility; geopolitical uncertainties cause extended transit times and higher insurance costs, increasing supply chain costs.
Geographies
4 verified
Europe market
Major revenue market alongside US; company expanding presence through business and R&D acquisitions in multiple European countries including Poland, Czech Republic, Netherlands, Spain, Belgium.
China and other international suppliers (44.0%)
44% of raw-material requirement sourced from China (including Hong Kong) for Key Starting Materials, Intermediates and APIs; critical supply chain dependency.
Japan
High-potential untapped market targeted for expansion; identified as emerging market with growth opportunity.
1 more statement
Middle East and Russia
High business risk regions due to political, economic, social and technological factors including local manufacturing push, import restrictions and mandatory government tender procurement.
Each statement is checked word for word against the FY2026 annual report; the passages are in the app.
What changed recently?
Q1 FY2027 results filed (5 Aug 2026).
Change log
6 entries · newest first
- Results filedQ1 FY2027 results filed.
- Results filedQ4 FY2026 results filed.
- Results filedQ3 FY2026 results filed.
- Results filedQ2 FY2026 results filed.
- Results filedQ1 FY2026 results filed.
- Results filedQ4 FY2025 results filed.
Get alerts →Sign in to be told when any of these change.
What this page does not tell you
What could not be judged, and why. Never empty.
- Models not runFair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored.
- FlagsWATCH on 30 of 30 flags judged; 1 red.
- Data gapsBusiness quality: not available yet.
What this page rests on
✓10 years of annual statements, through FY2026 (Mar-26)✓10 quarters of results✓285 months of month-end prices, adjusted for bonuses and splits○no valuation of ours yet✓business-model card FY2026 · 57 verified
Questions people ask
What is Aurobindo Pharma's share price today?
Aurobindo Pharma last traded at ₹1,706.90 on the NSE, as of 12 Oct 2026, 11:00 pm IST, up 0.8% on the day, up 48.9% over a year. Its 52-week range is ₹1,067 to ₹1,740. The live price is in the app.
What is Aurobindo Pharma's market cap?
Aurobindo Pharma's market capitalisation is about ₹97,411 crore: what it would cost to buy every share at today's price. That makes it the 22nd largest mid cap company we cover.
Is Aurobindo Pharma Ltd a large cap, mid cap or small cap?
Aurobindo Pharma Ltd (AUROPHARMA) is a mid cap company in AMFI's classification for Jan-Jun 2026. SEBI's buckets go by rank on six-month average market capitalisation: the top 100 are large caps, 101 to 250 mid caps, the rest small caps.
What is Aurobindo Pharma Ltd's P/E ratio?
26.45, vs peers 42.8 · 3rd of 23. Price divided by last year's earnings per share: how many years of today's profit you pay for.
Is Aurobindo Pharma Ltd overvalued?
Cheap, with low confidence: no valuation within 120 days; P/E 26.4 vs peers 42.8 (3rd of 23); P/B 3.3 vs peers 7.2 (7th of 25).
How does Aurobindo Pharma Ltd make money?
A multi-continent pharmaceutical company manufacturing and exporting active pharmaceutical ingredients (APIs) and finished formulations across 150+ countries. It earns revenue from sales of generic drugs, dermatology products, and specialty therapeutics to customers in regulated markets including the US, Europe, and growth markets, supported by a diversified portfolio of 728 approved products.
Who are Aurobindo Pharma Ltd's peers?
Compared with 24 Pharmaceuticals: Divis Laboratories Ltd, Torrent Pharmaceuticals Ltd, Zydus Lifesciences Ltd, Laurus Labs Ltd, Cipla Ltd and 19 more. The app shows how they compare on every figure.
Is this investment advice?
No. Valarth is a research and learning tool and is not a SEBI-registered investment adviser or research analyst. The figures come from the company's filings and the exchanges; what to do with them is your call.
How did Aurobindo Pharma do last quarter?
Aurobindo Pharma reported revenue of ₹9,106 Cr, up 6.1% on a year earlier and a net profit of ₹1,032 Cr, up 0.6% in the Jun 2026 quarter.
Who owns Aurobindo Pharma?
Aurobindo Pharma is held by promoters 51.9%, foreign institutions 16.4%, domestic institutions 25.1%.
Does Aurobindo Pharma pay a dividend?
Yes. Aurobindo Pharma's dividend yield is 0.31% at the latest price; the last payout was ₹4.00 a share, ex-dividend 8 Aug 2025.
What do analysts say about Aurobindo Pharma?
26 analysts cover Aurobindo Pharma, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.